Highlights for September 2017
- Zydus Cadila inks deal to produce varicella vaccine in Russia
- Fosun now aims for smaller Gland Pharma stake in $1.1B deal
- Panacea Biotec ties up with Canada’s Apotex to launch Prasugrel drug in US
- Eris Lifesciences acquires UTH Healthcare for ?12.85 crore
- Strides Shasun' arm Arrow Pharmaceuticals has acquired Australian operations of Amneal
- Selexis and OSE Immunotherapeutics expand strategic alliance
- Axxam signs up for CNS collaboration with French pharma major
- Merck, looking to build on cancer success, buys I-O biotech Rigontec
- Boehringer, Gubra strike backloaded €250M obesity deal
- Catalent doubles down on biologics with $950M deal for Cook Pharmica
- Janssen deal gives new kid in town Provention two immune candidates
- Arcus' cancer portfolio attracts $35M option deal from Japan's Taiho
- NewLink inks deal to evaluate I-O-based combinations
For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.
Updates at Aagami:
- A Happy client gives a long mandate for partnering in Asia region. Client is a Netherlands HQ'd company with a First-in-class phase-3-ready drug candidate for Post Operative Fibrosis (POF) with impeccable results
- JRF Global and Aagami conducted seminars on Futuristic Toxicology in collaboration with Rosalind Franklin University of Medical Sciences, Illinois Science and Technology Park and University of Connecticut
- Aagami completes a busy and fruitful BioPharm America 2017 along with extended business trip to New York and Connecticut